Keyphrases
Positron Emission Tomography
100%
Computed Tomography
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Network Studies
100%
Interim PET
100%
Direct Therapy
100%
National Clinical Trials Network
100%
PET-computed Tomography
100%
Limited-stage
100%
R-CHOP
42%
Overall Survival
28%
Treatment Strategy
28%
Survival Estimation
28%
R-CHOP Therapy
28%
Prednisone
14%
United States
14%
Progression-free Survival
14%
Improved Outcomes
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Lymphoma
14%
Radiation Therapy
14%
Excellent Outcome
14%
Rituximab
14%
90Y-ibritumomab Tiuxetan
14%
Radioimmunotherapy
14%
New Standards
14%
Doxorubicin
14%
Cyclophosphamide
14%
Advanced Stage Disease
14%
3-cycle
14%
Involved Site Radiation Therapy
14%
Rituximab Era
14%
Absolute Majority
14%
Interim Positron Emission Tomography/computed Tomography
14%
Disease Subsets
14%
Medicine and Dentistry
Positron Emission Tomography
100%
Clinical Trial
100%
Computer Assisted Tomography
100%
Diffuse Large B-Cell Lymphoma
100%
Polyethylene Terephthalate
87%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
62%
Diseases
50%
Overall Survival
25%
Rituximab
25%
Survival Estimate
25%
Radiation Therapy
25%
Positron Emission Tomography-Computed Tomography
12%
Progression Free Survival
12%
Prospective Study
12%
Radioimmunotherapy
12%
Doxorubicin
12%
Cyclophosphamide
12%
Prednisone
12%
Vincristine
12%
Ibritumomab Tiuxetan
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Diffuse Large B Cell Lymphoma
100%
Polyethylene Terephthalate
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
71%
Diseases
57%
Overall Survival
28%
Rituximab
28%
Prednisone
14%
Progression Free Survival
14%
Prospective Study
14%
Ibritumomab Tiuxetan
14%
Doxorubicin
14%
Cyclophosphamide
14%
Vincristine
14%
Immunology and Microbiology
Positron Emission Tomography
100%
B Cell
100%
Computer Assisted Tomography
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
62%
Overall Survival
25%
Rituximab
25%
Positron Emission Tomography-Computed Tomography
12%
Progression Free Survival
12%
Prednisone
12%
Cyclophosphamide
12%
Ibritumomab Tiuxetan
12%
Radiation Field
12%